JP2017516851A - 化合物及び筋肉の質を改善するためのその使用 - Google Patents
化合物及び筋肉の質を改善するためのその使用 Download PDFInfo
- Publication number
- JP2017516851A JP2017516851A JP2017513358A JP2017513358A JP2017516851A JP 2017516851 A JP2017516851 A JP 2017516851A JP 2017513358 A JP2017513358 A JP 2017513358A JP 2017513358 A JP2017513358 A JP 2017513358A JP 2017516851 A JP2017516851 A JP 2017516851A
- Authority
- JP
- Japan
- Prior art keywords
- group
- dimethyl
- cyclopenta
- trihydroxy
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 173
- 210000003205 muscle Anatomy 0.000 title claims abstract description 69
- 208000001076 sarcopenia Diseases 0.000 claims abstract description 30
- 208000008589 Obesity Diseases 0.000 claims abstract description 24
- 235000020824 obesity Nutrition 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 241000124008 Mammalia Species 0.000 claims abstract description 15
- 230000007170 pathology Effects 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 3
- -1 N-but-3-enoxy-C-methyl-carbonimidoyl Chemical group 0.000 claims description 59
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 28
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- CNVGWCFRCHOYCC-UHFFFAOYSA-N 4h-phenanthren-3-one Chemical compound C1=CC2=CC=CC=C2C2=C1C=CC(=O)C2 CNVGWCFRCHOYCC-UHFFFAOYSA-N 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 5
- IFYDTYZNOVCQIU-TWAYCVRHSA-N (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[1-(2-methoxyethylamino)ethyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one Chemical compound COCCNC(C)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)C3CC[C@]12C IFYDTYZNOVCQIU-TWAYCVRHSA-N 0.000 claims description 4
- LKKIKACVEQQEJH-XBNJWCGBSA-N (2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-17-[1-[2-methoxyethyl(methyl)amino]ethyl]-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one Chemical compound [H][C@@]12C[C@@H](O)[C@@H](O)C[C@]1(C)C1CC[C@]3(C)[C@H](CC[C@@]3(O)C1=CC2=O)C(C)N(C)CCOC LKKIKACVEQQEJH-XBNJWCGBSA-N 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000004899 motility Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- YFDVASAJEMAAKB-YLPQDLHOSA-N N-(2,2-difluoroethyl)-N-[1-[(2S,3R,5R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-6-oxo-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]furan-2-carboxamide Chemical compound [H][C@@]12C[C@@H](O)[C@@H](O)C[C@]1(C)C1CC[C@]3(C)[C@H](CC[C@@]3(O)C1=CC2=O)C(C)N(CC(F)F)C(=O)C1=CC=CO1 YFDVASAJEMAAKB-YLPQDLHOSA-N 0.000 claims description 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000007423 decrease Effects 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 49
- 108010056852 Myostatin Proteins 0.000 description 49
- 230000000694 effects Effects 0.000 description 39
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000001243 protein synthesis Methods 0.000 description 32
- 230000014616 translation Effects 0.000 description 31
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 27
- 238000005481 NMR spectroscopy Methods 0.000 description 27
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 27
- 239000000843 powder Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 238000000034 method Methods 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 210000002027 skeletal muscle Anatomy 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 239000012429 reaction media Substances 0.000 description 14
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 13
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- 230000035764 nutrition Effects 0.000 description 12
- 235000016709 nutrition Nutrition 0.000 description 12
- 230000026731 phosphorylation Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000009200 high fat diet Nutrition 0.000 description 9
- 210000003098 myoblast Anatomy 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000017854 proteolysis Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000000663 muscle cell Anatomy 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 206010006895 Cachexia Diseases 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 206010028289 Muscle atrophy Diseases 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- VNLQNGYIXVTQRR-UHFFFAOYSA-N Poststerone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(=O)C)CCC33O)C)C3=CC(=O)C21 VNLQNGYIXVTQRR-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000001195 anabolic effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 201000000585 muscular atrophy Diseases 0.000 description 6
- VNLQNGYIXVTQRR-NQPIQAHSSA-N poststerone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H](C(=O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 VNLQNGYIXVTQRR-NQPIQAHSSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002797 proteolythic effect Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 230000022379 skeletal muscle tissue development Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 5
- 241001519271 Ajuga Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108010074084 Muscle Proteins Proteins 0.000 description 5
- 102000008934 Muscle Proteins Human genes 0.000 description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 5
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 5
- 101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 230000004900 autophagic degradation Effects 0.000 description 5
- 229940125936 compound 42 Drugs 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000122 growth hormone Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 235000021283 resveratrol Nutrition 0.000 description 5
- 229940016667 resveratrol Drugs 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 229940127007 Compound 39 Drugs 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010056785 Myogenin Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229940126540 compound 41 Drugs 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 150000002061 ecdysteroids Chemical class 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002366 lipolytic effect Effects 0.000 description 4
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000004220 muscle function Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000007248 oxidative elimination reaction Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000037081 physical activity Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000003419 tautomerization reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 3
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 102000004364 Myogenin Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 3
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 3
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 3
- 102100038803 Somatotropin Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125807 compound 37 Drugs 0.000 description 3
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- WSBAGDDNVWTLOM-UHFFFAOYSA-N lesterone Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 WSBAGDDNVWTLOM-UHFFFAOYSA-N 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 230000009753 muscle formation Effects 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- WSBAGDDNVWTLOM-XHZKDPLLSA-N turkesterone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H]([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 WSBAGDDNVWTLOM-XHZKDPLLSA-N 0.000 description 3
- DXGPJKXCWRHUMH-UHFFFAOYSA-N turkesterone Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 DXGPJKXCWRHUMH-UHFFFAOYSA-N 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- PODGGBLQBAEANS-MWDDJPLISA-N (2R,3R)-2-[(2S,3R,5R,6Z,10R,13R,17S)-2,3-dihydroxy-6-methoxyimino-10,13-dimethyl-1,2,3,4,5,9,11,12,16,17-decahydrocyclopenta[a]phenanthren-17-yl]-6-methylheptane-2,3,6-triol Chemical compound [H][C@@]12C[C@@H](O)[C@@H](O)C[C@]1(C)C1CC[C@]3(C)[C@H](CC=C3C1=C\C2=N\OC)[C@@](C)(O)[C@H](O)CCC(C)(C)O PODGGBLQBAEANS-MWDDJPLISA-N 0.000 description 2
- NBAJZCQDCKUIKJ-RZFBPUJKSA-N (2S,3R,5R,10R,13S,14S,17S)-17-(N-but-3-enoxy-C-methylcarbonimidoyl)-2,3-dihydroxy-10,13-dimethyl-1,2,3,4,5,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-6-one Chemical compound [H][C@]12CC[C@H](C(C)=NOCCC=C)[C@@]1(C)CCC1C2=CC(=O)[C@]2([H])C[C@@H](O)[C@@H](O)C[C@]12C NBAJZCQDCKUIKJ-RZFBPUJKSA-N 0.000 description 2
- OGEJBBPFFLOZKJ-IWHAGXOISA-N (2S,3R,5R,10R,13S,17S)-17-acetyl-2,3-dihydroxy-10,13-dimethyl-1,2,3,4,5,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-6-one Chemical compound [H][C@@]12C[C@@H](O)[C@@H](O)C[C@]1(C)C1CC[C@]3(C)[C@H](CCC3C1=CC2=O)C(C)=O OGEJBBPFFLOZKJ-IWHAGXOISA-N 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 2
- 108010078606 Adipokines Proteins 0.000 description 2
- 102000014777 Adipokines Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 0 CC([C@@](CC1)[C@@](C)(CCC2[C@@](C)(C3)[C@@]4C[C@@](*)[C@]3O)C1C2=CC4=O)N* Chemical compound CC([C@@](CC1)[C@@](C)(CCC2[C@@](C)(C3)[C@@]4C[C@@](*)[C@]3O)C1C2=CC4=O)N* 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 240000006162 Chenopodium quinoa Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010069091 Dystrophin Proteins 0.000 description 2
- 102000001039 Dystrophin Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000690268 Homo sapiens Proline-rich AKT1 substrate 1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000003332 Ilex aquifolium Nutrition 0.000 description 2
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 2
- 235000002294 Ilex volkensiana Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000863193 Macaria Species 0.000 description 2
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 2
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010048654 Muscle fibrosis Diseases 0.000 description 2
- 102100038380 Myogenic factor 5 Human genes 0.000 description 2
- 102100038379 Myogenic factor 6 Human genes 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100024091 Proline-rich AKT1 substrate 1 Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 2
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 2
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000478 adipokine Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 102000001307 androgen receptors Human genes 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 238000003339 best practice Methods 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 2
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 208000037877 cardiac atrophy Diseases 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- JELQPNJFAFOBFW-UHFFFAOYSA-N cyclopenta[a]phenanthren-6-one Chemical compound C1=CC=C2C(=O)C=C3C4=CC=CC4=CC=C3C2=C1 JELQPNJFAFOBFW-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007368 endocrine function Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 101150046266 foxo gene Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 201000008319 inclusion body myositis Diseases 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 108010084677 myogenic factor 6 Proteins 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000000419 skeletal muscle satellite cell Anatomy 0.000 description 2
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 2
- 230000012488 skeletal system development Effects 0.000 description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 230000037221 weight management Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- KQHHJIGOXCKABS-GJUHZZJNSA-N (2S,3R,5R,10R,13R,14S,17S)-17-(2-ethoxyacetyl)-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one Chemical compound [H][C@@]12C[C@@H](O)[C@@H](O)C[C@]1(C)C1CC[C@]3(C)[C@H](CC[C@@]3(O)C1=CC2=O)C(=O)COCC KQHHJIGOXCKABS-GJUHZZJNSA-N 0.000 description 1
- XMQGVPFGFDASBV-VOYIJWMBSA-N (2S,3R,5R,6E,10R,13R,14S,17S)-17-[1-(2,2-difluoroethylamino)ethyl]-6-methoxyimino-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-2,3,14-triol Chemical compound CO\N=C1/C=C2C(CC[C@]3(C)[C@H](CC[C@@]23O)C(C)NCC(F)F)[C@@]2(C)C[C@H](O)[C@H](O)C[C@@H]12 XMQGVPFGFDASBV-VOYIJWMBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- ZYDROVAZLILMJR-TZLPMECJSA-N 1-[(2S,3R,5R,6E,10R,13R,14S,17S)-2,3,14-trihydroxy-6-methoxyimino-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound [H][C@@]12C[C@@H](O)[C@@H](O)C[C@]1(C)C1CC[C@]3(C)[C@H](CC[C@@]3(O)C1=C\C2=N/OC)C(C)=O ZYDROVAZLILMJR-TZLPMECJSA-N 0.000 description 1
- ZYDROVAZLILMJR-MCQJMRLTSA-N 1-[(2S,3R,5R,6Z,10R,13R,14S,17S)-2,3,14-trihydroxy-6-methoxyimino-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound [H][C@@]12C[C@@H](O)[C@@H](O)C[C@]1(C)C1CC[C@]3(C)[C@H](CC[C@@]3(O)C1=C\C2=N\OC)C(C)=O ZYDROVAZLILMJR-MCQJMRLTSA-N 0.000 description 1
- IPGVAZKAQUXIMP-MITSUZAESA-N 1-[(2S,3R,5R,6Z,10R,13R,17S)-2,3-dihydroxy-6-methoxyimino-10,13-dimethyl-1,2,3,4,5,9,11,12,16,17-decahydrocyclopenta[a]phenanthren-17-yl]ethanone Chemical compound [H][C@@]12C[C@@H](O)[C@@H](O)C[C@]1(C)C1CC[C@]3(C)[C@H](CC=C3C1=C\C2=N\OC)C(C)=O IPGVAZKAQUXIMP-MITSUZAESA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- OVRWUZYZECPJOB-UHFFFAOYSA-N 2,2-difluoroethanamine Chemical compound NCC(F)F OVRWUZYZECPJOB-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102400000347 Angiotensin 1-7 Human genes 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTCFCTSXENWJBT-UHFFFAOYSA-N C1CCC2=C(C1)C3=CC=C4C=CC=C4C3=CC2=O Chemical compound C1CCC2=C(C1)C3=CC=C4C=CC=C4C3=CC2=O BTCFCTSXENWJBT-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- GJJMPHQXMKVRGD-UDBMUEIZSA-N CC([C@@H](CC1)[C@@](C)(CCC([C@@](C)(C[C@@H]2O)[C@H]3C[C@H]2O)C2=CC3=O)[C@@]12O)N(CCOC)C(COC)O Chemical compound CC([C@@H](CC1)[C@@](C)(CCC([C@@](C)(C[C@@H]2O)[C@H]3C[C@H]2O)C2=CC3=O)[C@@]12O)N(CCOC)C(COC)O GJJMPHQXMKVRGD-UDBMUEIZSA-N 0.000 description 1
- WXWOGPXFJFBVDC-XSEDKLMMSA-N CCO/N=C(\C)/[C@@H](CC1)[C@@](C)(CCC([C@](C)(C[C@@H]2CC3=O)C[C@@H]3O)C3=CC2=O)[C@@]13O Chemical compound CCO/N=C(\C)/[C@@H](CC1)[C@@](C)(CCC([C@](C)(C[C@@H]2CC3=O)C[C@@H]3O)C3=CC2=O)[C@@]13O WXWOGPXFJFBVDC-XSEDKLMMSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241001268392 Dalla Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 101100351033 Mus musculus Pax7 gene Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 108700001591 MyoD Proteins 0.000 description 1
- 108010020197 Myogenic Regulatory Factor 5 Proteins 0.000 description 1
- 101710099061 Myogenic factor 5 Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000019204 Progranulins Human genes 0.000 description 1
- 108010012809 Progranulins Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 101710154918 Trigger factor Proteins 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- FZENGILVLUJGJX-UHFFFAOYSA-N acetaldehyde oxime Chemical compound CC=NO FZENGILVLUJGJX-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 108010021281 angiotensin I (1-7) Proteins 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000000636 anti-proteolytic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- YCNIBOIOWCTRCL-UHFFFAOYSA-N azane;2,2,2-trifluoroacetic acid Chemical compound [NH4+].[O-]C(=O)C(F)(F)F YCNIBOIOWCTRCL-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 244000195896 dadap Species 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000000403 lignoceroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960003377 metandienone Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 101150042523 myod gene Proteins 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- CZFNISFYDPIDNM-UHFFFAOYSA-N n,n-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60F—VEHICLES FOR USE BOTH ON RAIL AND ON ROAD; AMPHIBIOUS OR LIKE VEHICLES; CONVERTIBLE VEHICLES
- B60F3/00—Amphibious vehicles, i.e. vehicles capable of travelling both on land and on water; Land vehicles capable of travelling under water
- B60F3/0007—Arrangement of propulsion or steering means on amphibious vehicles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63C—LAUNCHING, HAULING-OUT, OR DRY-DOCKING OF VESSELS; LIFE-SAVING IN WATER; EQUIPMENT FOR DWELLING OR WORKING UNDER WATER; MEANS FOR SALVAGING OR SEARCHING FOR UNDERWATER OBJECTS
- B63C13/00—Equipment forming part of or attachable to vessels facilitating transport over land
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63B—SHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING
- B63B29/00—Accommodation for crew or passengers not otherwise provided for
- B63B29/02—Cabins or other living spaces; Construction or arrangement thereof
- B63B2029/022—Bathing platforms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63H—MARINE PROPULSION OR STEERING
- B63H11/00—Marine propulsion by water jets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63H—MARINE PROPULSION OR STEERING
- B63H25/00—Steering; Slowing-down otherwise than by use of propulsive elements; Dynamic anchoring, i.e. positioning vessels by means of main or auxiliary propulsive elements
- B63H25/42—Steering or dynamic anchoring by propulsive elements; Steering or dynamic anchoring by propellers used therefor only; Steering or dynamic anchoring by rudders carrying propellers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Combustion & Propulsion (AREA)
- Transportation (AREA)
- Mechanical Engineering (AREA)
- Emergency Medicine (AREA)
- Ocean & Marine Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
従って、サルコペニアを予防/治療する様々な方法が考察、試験されている。まず第一に運動であり、その有効性は確立されている(Bonnefoyら、2000年;Bonnefoy、2008年;Ryanら、2013年)。例えば、8週間の運動を行った後、筋力180%、筋肉量11%の増加が観察されている(Fiataroneら、1990年)。しかし、最適な有効性のためには1日当たり数時間の運動が必要であり、長期間にわたって想定することは難しい。
・テストステロンなどの性ホルモン(Whiteら、2013年)もしくはその変異体、SARM(選択的アンドロゲン受容体修飾剤)、又は成長ホルモン(Liuら、2003年)及びIGF−1、グレリンなどの非性ホルモン、又はプログラニュリン、又はビタミンD、
・ミオスタチン阻害剤(分子もしくはその受容体、又はミオスタチン前駆体ペプチドに対する抗体)(Murphyら、2010年;Han&Mitch、2011年)、
・ACE又はアンジオテンシン1−7の阻害剤など、レニン−アンジオテンシン系を標的とする分子(Dalla Liberaら、2001年;Shiuchiら、2004年;Kalupahana&Moustaid−Moussa、2012年;Allenら、2013年)、
・β−アドレナリン受容体アゴニスト(Ryallら、2004年、2007年)、
・多様な天然物質、又はさらにより複雑な植物由来の抽出物(例えば、イソフラボン:Aubertin−Leheudreら、2007年;オリーブオイル抽出物:Piernoら、2014年;レスベラトロール:Shadfarら、2011年;Bennettら、2013年)。
V−Uは炭素−炭素単結合であり、Yは水酸基又は水素であり、あるいはV−UはC=Cエチレン結合であり、
Xは、酸素;N−OR5基から選択され、
この時、R5は、水素;任意に鎖上に不飽和を有するC1−C6アルキル基;(C1−C6)CO2R6基(R6は場合により水素又はC1−C6基である);(C1−C6)OR7基(R7はアルキル又はアルコキシル基、CF3、Clで任意に一置換又は多置換された芳香族又は芳香族複素環である);(C1−C6)NR8R9基(R8及びR9はC1−C6基、又は(C1−C6)N(C1−C6)基もしくは(C1−C6)N(C1−C6)OR6基(R6は上記に定義)であり、またNR8R9は複素環でよい)から選択され、
また、式中、
Qはカルボニル基であり、
(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)CO2(C1−C6)基;(C1−C6)A基(Aは、OH、OMe、(C1−C6)、N(C1−C6)又はCO2(C1−C6)の種類の基で任意に置換された複素環を表す);CH2Br基から選択されるR1を有し、
Wは、N、O及びSから選択されるヘテロ原子であり、
あるいは、
QはCHOH基であり、
(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)CO2(C1−C6)基から選択されるR1を有し、
Wは、N及びSから選択されるヘテロ原子であり、
あるいは、
Qは、C=NOR5基(R5は上記に定義);CHNR2R3基から選択され、
(C1−C6)アルキル基であるR1を有し、
同一でも互いに異なっていてもよく、それぞれ水素原子;(C1−C6)アルキル基;(C1−C6)W(C1−C6)基;シクロアルキル基;(C1−C6)CHF2基;(C1−C6)A基(Aは、上記に定義した複素環を表す);COR4型の基から選択されるR2及びR3を有し、
R4は、任意に不飽和の(C1−C6)アルキル又はシクロアルキル基;OH、OMe、(C1−C6)、N(C1−C6)、CO2(C1−C6)、CF3、OCF3、CN、Cl、Fの種類の基で任意に置換された上記に定義したA型の複素環基、芳香族又は芳香族複素環基;(C1−C6)W(C1−C6)基から選択され、
Wは、N、O及びSから選択されるヘテロ原子であって、
エナンチオマー、ジアステレオ異性体、水和物、溶媒和物、互変異性体、ラセミ混合物又は医薬的に許容される塩の形である化合物を提供する。
Xは酸素であり、
V−Uは炭素−炭素単結合であり、
Yは水酸基であり、
Qはカルボニル基であり、
R1は、(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)CO2(C1−C6)基;(C1−C6)A基(Aは、OH、OMe、(C1−C6)、N(C1−C6)又はCO2(C1−C6)の種類の基で任意に置換された複素環を表す)から選択され、
Wは、N、O及びSから選択されるヘテロ原子である、化合物を使用する。
R4は、任意に不飽和の(C1−C6)アルキル又はシクロアルキル基;OH、OMe、(C1−C6)、N(C1−C6)、CO2(C1−C6)、CF3、OCF3、CN、Cl、Fの種類の基で任意に置換された上記に定義したA型の複素環基、芳香族又は芳香族複素環基;(C1−C6)W(C1−C6)基から選択される、化合物を使用する。
Xは酸素であり、
V−Uは炭素−炭素単結合であり、
Yは水酸基であり、
R1はメチル基であり、
QはCHNR2R3基であり、
水素原子;(C1−C6)アルキル基;(C1−C6)W(C1−C6)基;シクロアルキル基;(C1−C6)CHF2基;(C1−C6)A基(Aは上記に定義した複素環を表す);COR4型の基から選択されるR2及びR3を有し、
R4は、任意に不飽和の(C1−C6)アルキル又はシクロアルキル基;OH、OMe、(C1−C6)、N(C1−C6)、CO2(C1−C6)、CF3、OCF3、CN、Cl、Fの種類の基で任意に置換された上記に定義したA型の複素環基、芳香族又は芳香族複素環基;(C1−C6)W(C1−C6)基から選択され、
Wは、N、O及びSから選択されるヘテロ原子である、化合物を使用する。
Xは酸素であり、
V−Uは炭素−炭素単結合であり、
Yは水酸基であり、
R1はメチル基であり、
Qは、C=NOR5基(R5は上記に定義)である、化合物を使用する。
28:(2S,3R,5R,10R,13R,14S,17S)−17−(N−ブタ−3−エノキシ−C−メチル−カルボンイミドイル)−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
32:(2S,3R,5R,10R,13R,14S,17S)−17−(N−(2−ジエチルアミノエトキシ)−C−メチル−カルボンイミドイル)−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
41:2−メトキシ−N−(2−メトキシエチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]アセトアミド
42:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[1−(2−メトキシエチルアミノ)エチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
43:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−17−[1−(3−ピリジルメチルアミノ)エチル]−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
46:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−17−[1−(テトラヒドロフラン−2−イルメチルアミノ)エチル]−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
51:2−エチル−N−(2−メトキシエチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]ブタンアミド
62:2−メトキシ−N−(テトラヒドロフラン−2−イルメチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]アセトアミド
63:N−(テトラテトラヒドロフラン−2−イルメチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]フラン−2−カルボキサミド
67:N−(2,2−ジフルオロエチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]フラン−2−カルボキサミド
76:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[1−(2−メトキシエチル(メチル)アミノ)エチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
81:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−17−(2−モルホリノアセチル)−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
86:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[2−(3−ヒドロキシピロリジン−1−イル)アセチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
88:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[2−(4−ヒドロキシ−1−ピペリジル)アセチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
89:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[2−[4−(2−ヒドロキシエチル)−1−ピペリジル]アセチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
91:(2S,3R,5R,10R,13R,14S,17S)−17−[2−(3−ジメチルアミノプロピル(メチル)アミノ)アセチル]−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
92:2−[2−オキソ−2−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]スルファニルアセタートエチル
93:(2S,3R,5R,10R,13R,14S,17S)−17−(2−エチルスルファニルアセチル)−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
94:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[2−(2−ヒドロキシエチルスルファニル)アセチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン、
から選択される、一般式(I)の化合物を使用する。
(1)塩酸、臭化水素酸、硫酸、硝酸、リン酸などの無機酸;又は酢酸、ベンゼンスルホン酸、安息香酸、カンファースルホン酸、クエン酸、エタンスルホン酸、フマル酸、グルコヘプトン酸、グルコン酸、グルタミン酸、グリコール酸、ヒドロキシナフトエ酸、2−ヒドロキシエタンスルホン酸、乳酸、マレイン酸、リンゴ酸、マンデル酸、メタンスルホン酸、ムコン酸、2−ナフタレンスルホン酸、プロピオン酸、サリチル酸、コハク酸、ジベンゾイル−L−酒石酸、酒石酸、p−トルエンスルホン酸、トリメチル酢酸、トリフロオロ酢酸などの有機酸と形成された酸付加塩;あるいは、
(2)親化合物に存在する酸プロトンが、金属イオン、例えばアルカリ金属イオン、アルカリ土類金属イオンもしくはアルミニウムイオンで置き換えられるか、又は有機もしくは無機塩基と配位結合する時に形成される塩。許容される有機塩基は、ジエタノールアミン、エタノールアミン、N−メチルグルカミン、トリエタノールアミン、トロメタミンなどを含む。許容される無機塩基は、水酸化アルミニウム、水酸化カルシウム、水酸化カリウム、炭酸ナトリウム、及び水酸化ナトリウムを含む。
一般式(I)の化合物は、当業者に自体公知の任意の方法、及び/又は後半領域内、特にLarock(1989年)に記載のものを用いるか、適合させること、あるいは以下の手順に記載の工程を用いるか、適合させることにより調製することができる。
化合物A1から、スキームAに記載された酸化開裂により、化合物C1が得られる。この化合物は文献でポストステロンと呼ばれ、C20のカルボニルがR5ONH2型のアルコキシムの作用を受けて、化合物C2と、C6及びC20での二重反応から化合物C3と、C14−C15のヒドロキシルの脱離から化合物C4とを得ることができる。
スキームB由来の(E)及び(Z)配座異性体B3及びB’3の混合物を塩化チタンと反応させ、その作用により(Z)化合物B’3を脱水してD1が得られる。シアノ水素化ホウ素の存在下、R3NH2を用いて、前の工程で単離された化合物B3のC17のカルボニルを還元的アミノ化することで、化合物D2が得られ、酸塩化物R4COClをアシル化することで、化合物D3を得ることができる。
ポストステロンC1の還元的アミノ化を行った後、スキームDと同じタイプのアシル化を行い、化合物E1、その後E2を得ることができる。
スキームF由来の化合物E1の第2級アミンを、ブロモアルキル化合物を用いてアルキル化して、第3アミンF2が得られる。
ポストステロンC1のC21を、臭素を用いて臭素化して、臭素化化合物G1が得られ、これを求核試薬WR(Wは場合によりアミン又はチオール)でアルキル化して、化合物G2が得られる。
スキームGで得られた臭素化化合物G1を、OR型のアルコキシド化合物と反応させて、エーテル化合物H1が得られる。
水素化ホウ素ナトリウムを用い、スキームG由来の化合物G2をC20のカルボニルで還元して、アルコールI2が得られる。
スキームG由来の化合物G2を、スキームCに記載されたR5ONH2型のアルコキサミンとC20で反応させて、化合物J1を得ることができる。
プロトン(1H)核磁気共鳴(NMR)スペクトルをBruker Avance DPX300装置(300.16MHz)で行う。化学シフト(δ)を100万分率(ppm)で測定する。スペクトルを使用する重溶媒の化学シフトについて補正する。結合定数(J)をヘルツ(Hz)で表し、多重度を以下の様に、1重線(s)、2重線(d)、2重の2重線(dd)、3重線(t)、2重の3重線(td)、4重線(q)、多重線(m)で表す。マススペクトル(MS)を、アジレントテクノロジーMSD、G1946A型スペクトロメーターにより実施し、サンプルを「大気圧化学イオン化」(APCI)源によりイオン化する。
TBAF テトラブチルアンモニウムフルオリド
THF テトラヒドロフラン
DMF ジメチルホルムアミド
CDCl3 重クロロホルム
CD3OD 重メタノール
DMSO−d6 重ジメチルスルホキシド
PyBop (ベンゾトリアゾール−1−イルオキシ)トリピロリジノホスホニウムヘキサフルオロホスファート
Boc tert−ブチルオキシカルボニル
mmol ミリモル
μM マイクロモーラー
mL ミリリットル
g グラム
M モル/リットル
N 規定
nm ナノメートル
min 分
h 時
d 日
a.t. 周囲温度
UV 紫外線
ctrl コントロール
MW 分子量
MS 質量分析
化合物1及び2:
(2S,3R,5R,10R,13S,14S,17S)−17−(N−ブタ−3−エノキシ−C−メチルカルボンイミドイル)−2,3−ジヒドロキシ−10,13−ジメチル−1,2,3,4,5,9,11,12,14,15,16,17−ドデカヒドロシクロペンタ[a]フェナントレン−6−オン及び(2S,3R,5R,10R,13S,14R,17S)−17−(N−ブタ−3−エノキシ−C−メチルカルボンイミドイル)−2,3−ジヒドロキシ−10,13−ジメチル−1,2,3,4,5,9,11,12,14,15,16,17−ドデカヒドロシクロペンタ[a]フェナントレン−6−オンの調製
1H NMR(300MHz,DMSO−d6)δ5.72−5.43(m,1H(C7)),4.42−4.32(m,2H),4.13(s,1H),3.76−2.62(m,2H),3.2−3.1(m,2H),2.21−2.14(m,2H),1.90−1.02(m,28H),1.03−0.77(m,6H)。
1H NMR(300MHz,DMSO−d6)δ5.68−5.46(m,1H(C7)),4.41−4.37(m,2H),3.76−3.55(m,2H),2.83−2.54(m,2H),2.33−1.95(m,6H),1.90−1.30(m,10H),1.28−1.18(m,1H),0.88−0.42(m,6H)。
LC−MS:m/z=416.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)−C14βエピマー−δ5.83−5.72(m,1H)、5.70(s,1H(C7)),5.1−5(m,2H),4.40−4.36(m,2H),4(t,2H),3.77−3.71(m,2H),2.80−2.60(m,1H),2.40−1.20(m,20H),0.80−0.74(m,6H)。
LC−MS:m/z=416.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−D6)−C14αエピマー−δ5.87−5.72(m,1H),5.48(s,1H(C7)),5.1−4.9(m,2H),4.40−4.36(m,2H),4(t,2H),3.77−3.71(m,2H),2.80−2.60(m,1H),2.44−1.23(m,20H),0.83(s,3H),0.47(s,3H)。
化合物7:[1−[(2S,3R,5R,6Z,10R,13R,17S)−2,3−ジヒドロキシ−6−メトキシイミノ−10,13−ジメチル−1,2,3,4,5,9,11,12,16,17−デカヒドロシクロペンタ[a]フェナントレン−17−イル]エタノンオキシム]及び化合物19:[(2S,3R,5R,6E,10R,13R,14S,17S)−17−(N−(2−メトキシエトキシ)−C−メチルカルボンイミドイル)−6−メトキシイミノ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−2,3,14−トリオール]の調製
工程1:化合物(a)[(2S,3R,5R,6E,10R,13R,14S,17S)−6−メトキシイミノ−10,13−ジメチル−17−[(1R,2R)−1,2,5−トリヒドロキシ−1,5−ジメチル−ヘキシル]−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−2,3,14−トリオール]及び化合物(b)[(2R,3R)−2−[(2S,3R,5R,6Z,10R,13R,17S)−2,3−ジヒドロキシ−6−メトキシイミノ−10,13−ジメチル−1,2,3,4,5,9,11,12,16,17−デカヒドロシクロペンタ[a]フェナントレン−17−イル]−6−メチルヘプタン−2,3,6−トリオール]の調製
LC−MS:m/z=510.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ6.25(s,1H(C7)),4.45−4.35(m,3H),4.31−4.29(m,1H),4.14(s,1H),3.74−3.69(m,4H),3.6−3.5(m,1H),3.17−3.08(m,1H),2.87−2.75(m,1H),2.26−2.20(m,2H),2.05−1.1(m,15H),1.1−0.98(m,11H),0.73(s,6H)。
LC−MS:m/z=492.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ6.04(s,1H),5.77(s,1H),4.45−4.30(m,2H),4.25(s,1H),4.11(s,1H),3.75−3.65(m,5H),3.63−3.55(m,1H),3.20−3.08(m,2H),2.17−1.90(m,3H),1.70−1.20(m,11H),1.15−0.93(m,14H),0.74(s,3H)。
LC−MS:m/z=492.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ6.55(s,1H),5.81(s,1H),4.44−4.26(m,3H),4.09(s,1H),3.79−3.67(m,5H),3.62−3.54(m,1H),3.16−3.08(m,1H),2.30−1.90(m,4H),1.70−1.20(m,11H),1.15−0.92(m,14H),0.73(s,3H)。
LC−MS:m/z=374.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ6.09(s,1H),5.81−5.75(m,1H),4.39−4.37(m,1H),4.30−4.26(m,1H),3.76(s,3H),3.72−3.68(m,1H),3.65−3.55(m,1H),3.2−3(m,2H),2.75−2.60(m,1H),2.29−2.10(m,5H),1.74−1.23(m,8H),0.74−0.70(m,6H)。
LC−MS:m/z=389.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ10.53(s,1H),6.09(s,1H),5.04(s,1H),4.37(d,1H),4.30−4.26(m,1H),3.77−3.67(m,4H),3.65−3.55(m,1H),3.15−3.03(m,1H),2.80−2.65(m,2H),2.25−2.12(m,1H),2.05−1.99(m,1H),1.79(s,3H),1.74−1.20(m,8H),0.76−0.66(m,6H)。
工程2b:化合物(e):[1−[(2S,3R,5R,6E,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−6−メトキシイミノ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エタノン]及び(f):[1−[(2S,3R,5R,6Z,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−6−メトキシイミノ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エタノン]の調製
LC−MS:m/z=392.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ6.28(s,1H(C7)),4.74(s,1H),4.42−4.36(m,1H),4.32−4.28(m,1H),3.76−3.70(m,4H),3.68−3.52(m,1H),3.20−3.12(m,1H),2.90−2.76(m,1H),2.30−2.00(m,5H),1.90−1.50(m,8H),1.49−1.24(m,3H),0.72(s,3H),0.45(s,3H)。
LC−MS:m/z=392.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz、DMSO−d6)δ5.71(s,1H(C7)),4.45(s,1H),4.45−4.41(m,1H),4.26−4.23(m,1H),3.76−3.70(m,4H),3.65−3.55(m,1H),3.18−3.09(m,1H),2.90−2.80(m,1H),2.22−2.00(m,5H),1.88−1.22(m,11H),0.73(s,3H),0.47(s,3H)。
LC−MS:m/z=465.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ6.28(s,1H(C7)),4.66(s,1H),4.44−4.38(m,1H),4.34−4.28(m,1H),4.10−4.01(m,2H),3.75−3.70(m,4H),3.65−3.45(m,3H),3.24(s,3H),2.98−2.76(m,2H),2.30−1.90(m,4H),1.80−1.24(m,12H),0.73(s,3H),0.49(s,3H)。
化合物23:(2S,3R,5R,10R,13R,14S,17S)−17−(N−エトキシ−C−メチル−カルボンイミドイル)−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オンの調製
LC−MS:m/z=406.2(MH+)UV純度(254nm)=93%。
1H NMR(300MHz,CD3OD)δ5.82(s,1H(C7)),4.04(q,2H),3.97−3.92(m,1H),3.89−3.80(m,1H),3.22−3.10(m,1H),3.04(t,1H),2.43−1.55(m,15H),1.45−1.37(m,1H),1.21(t,3H),0.96(s,3H),0.64(s,3H)。
化合物37:N−(2,2−ジフルオロエチル)−N−[1−[(2S,3R,5R,6E,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−6−メトキシイミノ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]フラン−2−カルボキサミドの調製
LC−MS:m/z=457.4(MH+)UV純度(254nm)=97%。
1H NMR(300MHz,DMSO−d6)δ6.30−6.23(m,1H),5.95−5.70(m,1H),4.43−4.25(m,3H),3.72(s,3H),3.65−3.55(m,1H),3.42−3.32(m,1H),2.88−2.76(m,2H),2.29−2.23(m,1H),1.99−1.15(m,16H),1.05−0.82(m,3H),0.73(s,3H),0.61−0.53(m,3H)。
LC−MS:m/z=551.3(MH+)UV純度(254nm)=93%。
1H NMR(300MHz,DMSO−d6)δ7.87(s,1H),7.03(s,1H),6.64(s,1H),6.25(s,1H),4.58(d,1H),4.43−4.27(m,3H),3.95−3.83(m,1H),3.75−3.65(m,4H),3.63−3.49(m,2H),2.85−2.68(m,1H),2.31−2.18(m,1H),2.01−1(m,17H),0.73−0.15(m,6H)。
化合物41:2−メトキシ−N−(2−メトキシエチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]アセトアミドの調製
LC−MS:m/z=422.2(MH+)UV純度(254nm)=95%。
1H NMR(300MHz,DMSO−d6)δ5.70−5.60(m,1H(C7)),4.80−4.62(m,1H),4.55−4.47(m,1H),4.43−4.35(m,1H),3.78−3.70(m,2H),3.68−3.50(m,3H),3.30−3.18(m,5H),3.10−2.91(m,1H),2.30−0.9(m,18H),0.82(s,3H),0.59(s,3H)。
13C NMR(75MHz,DMSO−d6)δ202.9(C6),120.5,82.9,66.7,58.1,46.2,37.8,30.5,23.9,6.2。
LC−MS:m/z=494.4(MH+)UV純度(254nm)=94%。
1H NMR(300MHz,DMSO−d6)δ5.63(s,1H(C7)),4.88−4.7(m,1H),4.5−4.35(m,2H),4.2−3.9(m,2H),3.76(s,1H),3.68−3.52(m,1H),3.5−3.3(m,4H),3.28−3.18(m,6H),3.08−2.9(m,1H),2.3−0.95(m,18H),0.88−0.75(m,3H),0.7−0.42(m,3H)。
化合物76:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[1−(2−メトキシエチル(メチル)アミノ)エチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オンの調製
LC−MS:m/z=436.3(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ5.61(s,1H(C7)),4.64(s,1H),4.47−4.34(m,2H),3.75(s,1H),3.67−3.50(m,1H),3.25−3.16(m,5H),3.05−2.85(m,1H),2.27−1.15(m,20H),0.90−0.70(m,6H),0.59(s,3H)。
化合物81:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−17−(2−モルホリノアセチル)−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オンの調製
LC−MS:m/z=443.1(MH+)UV純度(254nm)=91%。
1H NMR(300MHz,DMSO−d6)δ5.69−5.63(m,1H(C7)),5.08(s,1H),4.42−4.35(m,3H),4.33−4.22(m,1H),3.77(s,1H),3.66−3.58(m,1H),3.39(t,1H),3.10−2.95(m,1H),2.25−1.20(m,13H),0.83(s,3H),0.51(s,3H)。
LC−MS:m/z=448.4(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ5.65(s,1H(C7)),5.02(s,1H),4.45(d,1H),4.40−4.37(m,1H),3.77(s,1H),3.68−3.53(m,5H),3.34−3.24(m,4H),3.08−2.95(m,1H),2.45−1.17(m,16H),0.82(s,3H),0.48(s,3H)。
化合物95:(2S,3R,5R,10R,13R,14S,17S)−17−(2−エトキシアセチル)−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オンの調製
LC−MS:m/z=407.2(MH+)UV純度(254nm)=93%。
1H NMR(300MHz,DMSO−d6)δ5.65−5.59(m,1H(C7)),4.96(s,1H),4.46(d,1H),4.41−4.36(m,1H),4.03(q,2H),3.77(s,1H),3.68−3.55(m,1H),3.08−2.90(m,1H),2.75−2.62(m,1H),2.3−2.15(m,2H),1.92−1.42(m,13H),1.18(t,3H),0.83(s,3H),0.58−0.49(m,3H)。
化合物97:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[1−ヒドロキシ−2−(2−ヒドロキシエチル(メチル)アミノ)エチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オンの調製
LC−MS:m/z=438.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz,DMSO−d6)δ5.6(s,1H(C7)),5.32−5.2(m,2H),4.77(s,1H),4.47(d,1H),4.42−4.38(m,1H),3.92−3.57(m,4H),3.3−2.95(m,4H),2.82(s,3H),2.31−1.18(m,16H),0.85(s,3H),0.69(s,3H)。
13C NMR(75MHz,DMSO−d6)δ203.2,164.9,121.0,82.8,66.9,59.0,55.6,50.6,46.9,40.7,37,34,31.9,31.1,30.3,24.5,23.2,20.4,16.3。
化合物101:(2S,3R,5R,6E,10R,13R,14S,17S)−6−メトキシイミノ−17−(N−メトキシ−C−(モルホリノメチル)カルボンイミドイル)−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−2,3,14−トリオールの調製
LC−MS:m/z=506.2(MH+)UV純度(254nm)=99%。
1H NMR(300MHz、DMSO−d6)δC6(Z)及び(E)配座異性体の混合物:6.28(s,0.45H(C7−E配座異性体),5.72(s,0.55H(C7−Z配座異性体),4.62(s,0.45H−E配座異性体),4.53(s,0.55H−Z配座異性体),4.47−4.35(m,1H),4.33−4.21(m,1H),3.77−3.70(m,7H),3.60−3.48(m,5H),3.16−3.06(m,1H),2.90−2.70(m,2H),2.45−1.20(m,18H),0.72(s,3H),0.64−0.57(m,3H)。
スクリーニング試験の開発を文献における研究に基づき開始し、サルコペニア病変の特性を基準とした。生理病理学レベルで、この疾患は、タンパク質合成減少及びタンパク質分解増加により特徴付けられる。従って、次世代の薬剤の開発は、これら2つの現象に関する分子因子についてスクリーニングされるべきである。
C2C12細胞におけるミオスタチン発現の阻害:
C2C12筋芽細胞(ATCC CRL−1772)を24ウェルプレートに1ウェル当たり細胞30000個の密度で播種し、4.5g/lの割合でグルコースを含有し、ウシ胎仔血清(10%)と、抗生物質(ペニシリン及びストレプトマイシン)を添加したDMEM培地で培養した。48時間後、5日間、部分血清枯渇(10%ではなく2%)により、筋芽細胞の分化を誘導する。その後、試験分子又は標準物(100ng/mlのIGF−1もしくは10μMの20E)の存在下、6時間、グルコース枯渇、無血清の培地(1g/lグルコース含有DMEM)に細胞を入れる。実験の終わりに、フェノール及びクロロホルムを用いる従来の方法によりメッセンジャーRNA(mRNA)を抽出する。簡潔に述べると、細胞を強酸及びフェノールを含有するTrizol溶液(シグマT9424)で溶解する。クロロホルムの添加後、遠心分離によりmRNAをタンパク質から分離する。次に、イソプロパノールで析出させた後、RNaseフリーDNaseフリー超純水に1μg/μlの濃度で懸濁する。その後、供給元(アプライドバイオシステムズ4368814)のプロトコールに従って、プライマー及びヌクレオチド混合物の存在下、AMV酵素により、1μgのmRNAを逆転写によって相補的DNAに変換する。連鎖反応により遺伝子発現を調査する。この連鎖反応は、ポリメラーゼ酵素により開始し、通常定量的条件のPCRと言われるため、具体名はqPCRである。qPCRを7900HT FastリアルタイムPCR検出システム(アプライドバイオシステムズ)によって実施する。プログラム条件は標準であり、95℃15分の1サイクル、続いて95℃15秒、60℃1分の40サイクルからなり、プログラムは60〜95℃の融解曲線工程で終了する。分析サンプルはすべて100ngのcDNA、酵素を含むqPCRバッファー、オリゴヌクレオチド混合物、及びインターカレート剤(サイバーグリーン、SYBRgreen)と、戦略的に2つのエクソン配列から選択され、最終濃度200nMの被験遺伝子に特異的なプライマー対を含有する。蛍光プローブは、二本鎖DNAに結合し、DNAに結合したときのみ蛍光を発する。蛍光閾値は機械のプログラムにより設定する。DNA量により蛍光プローブがこの閾値を越えるとき、PCRサイクル数が得られ、「Cycle Threshold」から「Ct」と呼ばれる。この値は、それぞれDNAを定量する計算の基礎となる。サンプル、及びコントロール(未処置)間の初期DNA量の比Rが求められ(すなわち、R=2-(Ctサンプル-Ctコントロール))、この測定値は、処置により修飾されないことが知られるハウスキーピング遺伝子に関係する(すなわち、R=2-ΔΔCt)。
C2C12筋芽細胞(ATCC CRL−1772)を6ウェルプレートに1ウェル当たり細胞170000個の密度で播種し、4.5g/lの割合でグルコースを含有し、ウシ胎仔血清(10%)と、抗生物質(ペニシリン及びストレプトマイシン)を添加したDMEM培地で培養する。48時間後、5日間、部分血清枯渇(10%ではなく2%)により、筋芽細胞の分化を誘導する。その後、試験分子又は標準物(100ng/mlのIGF−1もしくは10μMの20E)の存在下、2時間、グルコース枯渇、無血清の培地(1g/lのグルコース含有DMEM)に細胞を入れる。実験の終わりに、市販の抗タンパク分解酵素混合物(ロシュ05056489001)を添加した市販の溶解バッファー(インビトロジェンFNN0011)で細胞を溶解する。遠心分離後、可溶性タンパク質を含む細胞質画分を保持し、タンパク質濃度を市販のキット(バイオラッド500−0114)を用いて決定する。このキットの原理は、ローリー法による分析から構成される。S6キナーゼリン酸化反応の分析を市販のELISA(Enzyme Linked ImmunoSorbend Assay)キット(セルシグナリング7063)を用いて行う。簡潔に述べると、タンパク質溶解物50μgを96ウェルマイクロプレートのウェルに入れ、pS6キナーゼトレオニン389抗体に特異的な抗原の溶液と4℃で一晩インキュベートする。抗原をウェル底に静電的に結合する。その後、分析する抗体(pS6K T389)の溶液を、37℃で2時間、ウェルでインキュベートする。抗体が抗原に特異的に結合する。その後、ウェルを洗浄バッファで洗浄して、過剰な分析する抗原特異的1次抗体を除去する。第3工程は、検出抗体を結合することである。検出抗体の溶液を37℃で1時間、ウェルでインキュベートする。その後、ウェルを洗浄して、過剰な検出抗体を除去する。なお、検出抗体が酵素に結合し、この酵素によって、基質の存在下、着色の様子により検出、測定することができる反応生成物に変換される。最終工程は、結合抗体を明らかにすることである。酵素(この場合TMB(3,3’,5,5’−テトラメチルベンジジン))の基質を含有する露出溶液を、暗所において37℃で30分インキュベートする。基質の青色着色は、被分析抗体の存在を示す。任意の飽和現象を防止するため、停止溶液(一般に、水酸化ナトリウムを含む)を添加し、青から黄色に変化させる。その強さは、存在する酵素量、従って探索する抗体濃度に比例する。シグナル強度は、波長450nmで分光測定法により測定する。
比較化合物としての20Eと、本発明化合物(51及び93)を、6週間、高脂肪飼料を摂取した12週齢のC57BL/6Jマウスに、5mg/体重kgの投与量で経口投与した。ヒラメ筋の重量及びタンパク質量、また筋形成に関わる遺伝子の転写産物に対する化合物の効果を評価した。
化合物の薬物動態を雄のウィスター系ラット(チャールズリバー)を経口的に用いて評価した。比較化合物としての20Eを、50mg/体重kgの投与量で投与した。本発明の新規化合物は、4〜6生成物の混合物の形で10mg/体重kgの投与量で投与した。投与後、t=0.25h、0.5h、1h、3h、6h及び8hに尾から血液をサンプリングした。血液サンプルを遠心分離し、血漿を除いた。血漿サンプルの分析により、薬物動態パラメーター、すなわち分子の投与後に観察される最大濃度に相当するCmax、分子の投与後、最大濃度に達するのに要する時間であるTmax、及び各サンプリング時間の各化合物濃度で構成された曲線下の面積であるAUCを決定することができる。
ミオスタチン発現に対する効果
6週間、高脂肪飼料を摂取したC57BL/6マウスに、5mg/体重kgの投与量で経口投与した比較化合物としての20Eと、本発明の分子(51及び93)の効果を評価することにより、in vivoでの調査を行う。ヒラメ筋の重量及びタンパク質量と、筋形成に関わる遺伝子の転写産物に対する分子の効果を評価した。
化合物を10mg/kg、20Eを50mg/kgの投与量で経口投与し、20E及び本発明の化合物の薬物動態をラットにおいて評価した。
図6に示す表は、ミオスタチン遺伝子発現及びタンパク質合成の分析実験中に本発明の化合物で得られた結果を示す。
Arounleut P,Bialek P, Liang LF,et al.2013.A myostatin inhibitor (propeptide−Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength. Exper Gerontol 48:898−904.
Aubertin−Leheudre M, Lord C, Khalil A, Dionne IJ. 2007. Six months of isoflavone supplement increases fat−free mass in obese−sarcopenic postmenopausal women:a randomized double−blind controlled trial. Eur J Clin Nutr 61:1442−1444.
Aussel C,Woelffle E,Lemoigne P,Depailler L,Bouillanne O.2013.Une nouvelle strategie nutritionnelle pour lutter contre la denutrition et la sarcopenie:le regime proteique pulse[A novel nutritional strategy for combating undernutritionment and sarcopenia:the pulsed protein diet]. Cahiers Nutrition Dietetique 48:33−40.
Azizov AP,Seifulla RD,Ankudinova IA,Kondrat’eva II,Borisova IG.1998.Effect of the antioxidants elton and leveton on the physical work capacity of athletes.Eksp Klin Farmakol 61(1):60−62.
Baptista IL,Leal ML, Artioli GG, et al.2010.Leucine attenuates skeletal muscle wasting via inhibition of ubiquitin ligases.Muscle Nerve 41(6):800−808.
Bathori M,Toth N,Hunyadi A,Marki A,Zador E.(2008).Phytoecdysteroids and anabolic−androgenic steroids − Structure and effects on Humans.Current Medicinal Chemistry 15:75−91.
Bennett BT,Mohamed JS,Alway SE.2013.Effects of resveratrol on the recovery of muscle mass following disuse in the plantaris muscle of aged rats.PLoS One 8(12):e83518.
Boirie Y,Gachon P,Beaufrere B.1997.Splanchnic and whole body leucine kinetics in young and elderly men.Am J Clin Nutr.65:489−495.
Bonnefoy M,Constans T,Ferry M.2000.Denutrition du sujet age.Influence de la nutrition et de l’activite physique sur le muscle au grand age[Undernutritionment in the elderly.Influence of nutrition and physical activity on muscle in old age].Presse Med 29:2177−2182.
Bonnefoy M.2008.Interventions pour restaurer la masse musculaire chez le sujet age [Interventions for restoring muscle mass in the elderly].Nutr Clin Metab 22:80−83.
Buehring B, Binkley N.2013.Myostatin − the holy grail for muscle,bone,and fat?Curr Osteoporos Rep 11(4):407−414.
Castan−Laurell I,Dray C,Knauf C,Kunduzova O,Valet P.2012.Apelin,a promising target for type 2 diabetes treatment?Trends Endocrinol Metab 23(5):234−241.
Chermnykh NS,Shimanovsky NL,Shutko GV,Syrov VN.1988.Effects of methandrostenolone and ecdysterone on physical endurance of animals and protein metabolism in the skeletal muscles.Farmakologiya i Toksikologiya6:57−62.
Coeffier M,Petit A,Dechelotte P.2009.Quelle pharmaconutrition pour lutter contre la sarcopenie?[Which pharmaconutrition for combating sarcopenia?]Nutrition Clinique Metabolisme 23:76−79.
Collins−Hooper H,Sartori R,Macharia R,et al.2014.Propeptide−mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice.J Gerontol A Biol Sci Med Sci,doi:10.1093/gerona/gh170.
Crenn P.2013.Sarcopenie et cachexie:approche medicamenteuse[Sarcopenia and cachexia:a drug approach].Nutrition Clinique Metabolisme 27:69−73.
de Jager N,Hudson NJ,Reverter A,et al.2011.Chronic exposure to anabolic steroids induces the muscle expression of oxytocin and a more than fiftyfold increase in circulating oxytocin in cattle.Physiol Genomics 43:467−478.
Dumonceaux J,Marie S,Beley C,Trollet C,Vignaud A,Ferry A,Butler−Browne G,Garcia L.2010.Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice.Mol Ther 18(5):881−887.
Fiatarone MA,Marks EC, Ryan ND,Meredith CN,Lipsitz LA,Evans WJ.1990.High−intensity strength training in nonagerians. JAMA 263:3029−3034.
Foucault AS,Mathe V,Lafont R,Even P,Dioh W,Veillet S,Tome D,Huneau D,Hermier D,Quignard−Boulange A.2012.Quinoa extract enriched in 20−hydroxyecdysone protects mice from diet−induced obesity and modulates adipokines expression.Obesity 20:270−277.
Foucault AS,Dioh W,Lafont R,Veillet S,Tome D,Quignard−Boulange A,Clement K,Rizkalla S.2014.20−Hydroxyecdysone increases android fat mass loss with no significant effect on muscle mass loss during a weight loss program in obese and overweight subjects.ICFSR 2014 International Conference of Frailty and Sarcopenia Research, Barcelona,12−14/03/2014.
Gadzhieva RM, Portugalov SN,Paniushkin VV, Kondrat’eva II.1995.A comparative study of the anabolic action of ecdysten,leveton and Prime Plus, preparations of plant origin.Eksp Klin Farmakologiya 58(5): 46−48.
Gilson H, Schakman O,Combaret L,et al.2007.Myostatin gene deletion prevents glucocorticoid−induced muscle atrophy.Endocrinology 148:452−460.
Gorelick−Feldman J,MacLean D,Ilic N,Poulev A,Lila MA,Raskin I.2008.Phytoecdysteroids increase protein synthesis in skeletal muscle cells.J.Agric.Food Chem.56:3532−3537.
Gorelick−Feldman J,Cohick W,Raskin I.2010.Ecdysteroids elicit a rapid Ca2+ flux leading to Akt activation and increased protein synthesis in skeletal muscle cells. Steroids 70:632−637.
Greenberg SA.2012.Pathogenesis and therapy of inclusion body myositis.Curr Opin Neurol 25(5):630−639.
Han HQ,Mitch WE.2011.Targeting the myostatin signaling pathway to treat muscle wasting diseases.Curr Opin Support Palliat Care 5(4):334−341.
Hung TJ,Chen WM, Liu SF,et al.2012.20−Hydroxyecdysone attenuates TGF−β1−induced renal cellular fibrosis in proximal tubule cells.J Diabetes Complications 26(6):463−469.
Kazi AA,Lang CH 2010.PRAS40 Regulates Protein Synthesis and Cell Cycle in C2C12 Myoblasts Mol Med.16(9−10):359−371.
Kizelsztein P,Govorko D,Komarnytsky S,Evans A,Wang Z,Cefalu WT,Raskin I.2009.20−Hydroxyecdysone decreases weight and hyperglycemia in a diet−induced obesity mice model.Am.J.Physiol.Endocrinol.Metab.296:E433−E439.
KnightJDR, Kothary R.2011.The myogenic kinome:protein kinases critical tomammalian skeletal myogenesis Skeletal Muscle,1:29,
http://www.skeletalmusclejournal.com/content/1/1/29
Lafont R,Clement K,Rizkalla S,Foucault AS,Veillet S,Dioh W.2013 Phytoecdysones for use in weight stabilization after a weight−loss diet.PCT patent application WO 2013/068704
Lafont R,Harmatha J,Marion−Poll F,Dinan L,Wilson ID.2002.Ecdybase,a free ecdysteroid database.http://ecdybase.org
Larock RC.1989.Comprehensive organic transformations:A guide to functional group preparations.VCH Publishers,New York.
Lawrence MM.2012.Ajuga turkestanica as a countermeasure against sarcopenia and dynapenia.Ms thesis,Appalachian State University.
Le Grand F,Rudnicki MA.2007.Skeletal muscle satellite cells and adult myogenesis.Curr Opin Cell Biol,19:628−633.
Leger B,Derave W,De Bock K; Hespel P,Russell AP.2008.Human sarcopenial reveals an increase in SOCS−3 and myostatin and a reduced efficiency of Akt phosphorylation.Rejuvenation Res 11(1):163−175.
Li Z,Heber D.2011.Sarcopenic obesity in the elderly and strategies for weight management.Nutrition Reviews 70(1):57−64.
Li ZB,Kollias HD,Wagner KR.2008.Myostatin directly regulates skeletal muscle fibrosis.J.Biol.Chem.283(28):19371−19378.
Little JP,Phillips SM.2009.Resistance exercise and nutrition to counteract muscle wasting.Appl Physiol Nutr Metab 34:817−828.
Liu W,Thomas SG,Asa SL,et al.2003.Myostatin is a skeletal muscle target of growth hormone anabolic action.J Clin Endocr Metab 88(11):5490−5496.
Macell TJ,Harman SM,Urban RJ,et al.2001.Comparison of GH,IGF−I,and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men.Am J Physiol Endocrinol Metab 281:E1159−E1164.
Murad MH,Elamin KB,Abu Elnour NO,et al.2011.Clinical review:the effect of vitamin D on falls:a systematic review and meta−analysis.J Clin Endocrinol Metab 96(10):2997−3006.
Murphy KT,Koopman R,Naim T,et al.2010.Antibody−directed myostatin inhibition in 21−mo−old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function.FASEB J 24:4433−4442.
Pierno S,Tricarico D,Liantonio A,et al.2014.An olive oil−derived antioxidant mixture ameliorates the age−related decline of skeletal muscle function. AGE 36:73−88.
Quillot D,Bohme P,Malgras P,Malgras A,Ziegler O.2013.L’obesite du sujet age[Obesity in the elderly].Nutr Clin Metabolisme 27:95−101.
Ryall JG,Plant DR,Gregorevic P,Silence MN,Lynch GS.2004.β2−Agonist administration reverses muscle wasting and improves muscle function in aged rats.J Physiol 555(1):175−188.
Ryall JG,Church JE,Lynch GS.2007.A novel role of β−adrenoreceptor signalling in skeletal muscle growth,development and regeneration.Proc Australian Physiol Soc 40:103−108.
Ryan AS,Li G, Blumenthal JB,Ortmeyer HK.2013.Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults.Obesity 21(7):1350−1356.
Sabourin LA,Rudnicki MA.2000.The molecular regulation of myogenesis.Clin Genet 57:16−25.Saini A,Faulkner S,AL−Shanti N,Stewart C.2009.Powerful signals for weak muscles.Ageing Res Rev 8:251−267.
Sakuma K,Yamaguchi A. 2012.Sarcopenia and age−related endocrine function.Int J Endocrinol,doi:10.1155/2012/127362.
Sattler FR.2013.Growth hormone in the aging male.Best Practice Res Clin Endocr Metab 27:541−555.
Schaap LA,Pluijm SMF,Deeg DJH,et al.2009. Higher inflammatory marker levels in older persons:associations with 5−year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 64A(11):1183−1189.
Seidlova−Wuttke D,Erhardt C,Wuttke W.2010.Metabolic effects of 20−OH ecdysone in ovariectomized rats.J Steroid Biochem Mol Biol 119:121−126.
Seidman SN.2007.Androgens and the aging male.Psychopharmacol Bull 40:205−218.
Shadfar S,Couch ME, McKinney KA,et al.2011.Oral resveratrol therapy inhibits cancer−induced skeletal muscle and cardiac atrophy in vivo.Nutr Cancer 63(5):749−762.
Simakin SYu,Panyushkin VV,Portugalov SN,Kostina LV,Martisorov EG.1988.Combined application of preparation Ecdysten and product Bodrost during training in cyclic sports.Sports Science Bulletin No2,29−31.
Stenholm S,Alley D,Bandinelli S,et al.2009.The effect of obesity combined with low muscle strength on decline in mobility in older persons:results from the InCHIANTI study.Int J Obesity 33:635−644.
Syrov VN.2000.Comparative experimental investigations of the anabolic activity of ecdysteroids and steranabols.Pharm Chem Journal 34(4):193−197.
Syrov VN, Saatov V,Sagdullaev ShSh,Mamatkhanov AU.(2001).Study of the structure ? anabolic activity relationship for the phytoecdysteroids extracted from some plants of central Asia. Pharmaceutical Chemistry Journal35:667−671.
Tchoukouegno Ngueu S.2013.Estrogenic,cytotoxic and anabolic effects on estrogen target organs of an extract of Erythrina excelsa and ecdysterone.PhD thesis,German Sports University of Cologne.
Tisdale MJ. 2001. Facteurs lipolytiques et proteolytiques de la cachexie cancereuse[Lipolytic and proteolytic factors of cancer−related cachexia].Nutr Clin Metabol 15:266−272.
Todorov IN,Mitrokhin YuI,Efremova OI,Sidorenko LI.2000.The effect of ecdysterone on the biosynthesis of proteins and nucleic acids in mice.Pharmaceut Chem J 34(9):455−458.
Toth N,Szabo A,Kacsala P,Heger J,Zador E.2008.20−Hydroxyecdysone increases fiber size in a muscle−specific fashion in rat.Phytomedicine 15:691−698.
Verghese J,Holtzer R,Oh−Park M,et al.2011.Inflammatory markers and gait speed decline in older adults.J Gerontol A Biol Sci Med Sci 66A:1083−1089.
Walston JD.2012.Sarcopenia in older adults.Curr.Opinion Rheumatol.24:623−627.
White JP,Gao S,Puppa MJ,et al.2013.Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle. Mol Cell Endocrinol 365:174−186.
White TA,LeBrasseur,NK.2014.Myostatin and sarcopenia:opportunities and challenges − a mini−review.Gerontology,doi:10.1159/000356740.
Wuttke W, Seidlova−Wuttke D.2013.Pflanzliche Praparate fur die Therapie klimaterischer und postmenopausaler Beschwerden und Erkrankungen. Frauenartz 54:580−587.
Zhao J,Brault JJ,Schild A,Goldberg AL.2008.Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor.Autophagy 4(3):378−380.
Zhu WM,Zhu HJ,Tian WS,Hao XJ,Pittman Jr CU.2002.The selective dehydroxylation of 20−hydroxyecdysone by Zn powder and anhydrous acetic acid.Synthetic Communications 32:1385−1391.
Zubeldia JM, Hernandez−Santana A,Jimenez−de−Rio M,et al.2012.In vitro characterization of the efficacy and safety profile of a proprietary Ajuga turkestanica extract.Chinese Medicine 3:215−222.
Claims (13)
- 下記一般式(I)の化合物
V−Uは炭素−炭素単結合であり、Yは水酸基又は水素であり、あるいはV−UはC=Cエチレン結合であり、
Xは、酸素;N−OR5基から選択され、
この時、R5は、水素;任意に鎖上に不飽和を有するC1−C6アルキル基;(C1−C6)CO2R6基(R6は場合により水素又はC1−C6基である);(C1−C6)OR7基(R7はアルキル又はアルコキシル基、CF3、Clで任意に一置換又は多置換された芳香族又は芳香族複素環である);(C1−C6)NR8R9基(R8及びR9はC1−C6基、又は(C1−C6)N(C1−C6)基もしくは(C1−C6)N(C1−C6)OR6基(R6は上記に定義)であり、またNR8R9は複素環でよい)から選択され、
また、式中、
Qはカルボニル基であり、
(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)CO2(C1−C6)基;(C1−C6)A基(AはOH、OMe、(C1−C6)、N(C1−C6)又はCO2(C1−C6)の種類の基で任意に置換された複素環を表す);CH2Br基から選択されるR1を有し、
Wは、N、O及びSから選択されるヘテロ原子であり、
あるいは、
QはCHOH基であり、
(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)CO2(C1−C6)基から選択されるR1を有し、
Wは、N及びSから選択されるヘテロ原子であり、
あるいは、
Qは、C=NOR5基(R5は上記に定義);CHNR2R3基から選択され、
(C1−C6)アルキル基であるR1を有し、
同一でも互いに異なっていてもよく、それぞれ水素原子;(C1−C6)アルキル基;(C1−C6)W(C1−C6)基;シクロアルキル基;(C1−C6)CHF2基;(C1−C6)A基(Aは上記に定義した複素環を表す);COR4型の基から選択されるR2及びR3を有し、
R4は、任意に不飽和の(C1−C6)アルキル又はシクロアルキル基;OH、OMe、(C1−C6)、N(C1−C6)、CO2(C1−C6)、CF3、OCF3、CN、Cl、Fの種類の基で任意に置換された上記に定義したA型の複素環基、芳香族又は芳香族複素環基;(C1−C6)W(C1−C6)基から選択され、
Wは、N、O及びSから選択されるヘテロ原子であって、
エナンチオマー、ジアステレオ異性体、水和物、溶媒和物、互変異性体、ラセミ混合物又は医薬的に許容される塩の形である、化合物。 - 式(I)中、Qはカルボニル基を表す、請求項1に記載の化合物。
- 請求項2に記載の化合物であって、式(I)中、
Xは酸素であり、
V−Uは炭素−炭素単結合であり、
Yは水酸基であり;
R1は、(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)W(C1−C6)基;(C1−C6)W(C1−C6)CO2(C1−C6)基;(C1−C6)A基(Aは、OH、OMe、(C1−C6)、N(C1−C6)又はCO2(C1−C6)の種類の基で任意に置換された複素環を表す)から選択され、
Wは、N、O及びSから選択されるヘテロ原子である、化合物。 - 式(I)中、QはC=NOR5基(R5は上記に定義)を表す、請求項1に記載の化合物。
- 請求項4に記載の化合物であって、式(I)中、
Xは酸素であり、
V−Uは炭素−炭素単結合であり、
Yは水酸基であり、
R1はメチル基である、化合物。 - 請求項1に記載の化合物であって、式(I)中、QはCHNR2R3基(R2及びR3は、同一でも互いに異なっていてもよく、それぞれ水素原子;(C1−C6)アルキル基;(C1−C6)W(C1−C6)基;シクロアルキル基;(C1−C6)CHF2基;(C1−C6)A基(Aは上記に定義した複素環を表す);COR4型の基から選択される)を表し、
R4は、任意に不飽和の(C1−C6)アルキル又はシクロアルキル基;OH、OMe、(C1−C6)、N(C1−C6)、CO2(C1−C6)、CF3、OCF3、CN、Cl、Fの種類の基で任意に置換された上記に定義したA型の複素環基、芳香族又は芳香族複素環基;(C1−C6)W(C1−C6)から選択される、化合物。 - 請求項6に記載の化合物であって、式(I)中、
Xは酸素であり、
V−Uは炭素−炭素単結合であり、
Yは水酸基であり、
R1はメチル基であり、
Wは、N、O及びSから選択されるヘテロ原子である、化合物。 - 式(I)中、V−UはC=Cエチレン結合である、請求項1に記載の化合物。
- 式(I)中、XはN−OR5基である、請求項1に記載の化合物。
- 請求項1〜9のいずれか一項に記載の化合物であって、以下の化合物:
28:(2S,3R,5R,10R,13R,14S,17S)−17−(N−ブタ−3−エノキシ−C−メチル−カルボンイミドイル)−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
32:(2S,3R,5R,10R,13R,14S,17S)−17−(N−(2−ジエチルアミノエトキシ)−C−メチル−カルボンイミドイル)−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
41:2−メトキシ−N−(2−メトキシエチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]アセトアミド
42:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[1−(2−メトキシエチルアミノ)エチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
43:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−17−[1−(3−ピリジルメチルアミノ)エチル]−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
46:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−17−[1−(テトラヒドロフラン−2−イルメチルアミノ)エチル]−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
51:2−エチル−N−(2−メトキシエチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]ブタンアミド
62:2−メトキシ−N−(テトラヒドロフラン−2−イルメチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]アセトアミド
63:N−(テトラテトラヒドロフラン−2−イルメチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]フラン−2−カルボキサミド
67:N−(2,2−ジフルオロエチル)−N−[1−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]フラン−2−カルボキサミド
76:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[1−(2−メトキシエチル(メチル)アミノ)エチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
81:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−17−(2−モルホリノアセチル)−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
86:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[2−(3−ヒドロキシピロリジン−1−イル)アセチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
88:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[2−(4−ヒドロキシ−1−ピペリジル)アセチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
89:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[2−[4−(2−ヒドロキシエチル)−1−ピペリジル]アセチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
91:(2S,3R,5R,10R,13R,14S,17S)−17−[2−(3−ジメチルアミノプロピル(メチル)アミノ)アセチル]−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
92:2−[2−オキソ−2−[(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−10,13−ジメチル−6−オキソ−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−17−イル]エチル]スルファニルアセタートエチル
93:(2S,3R,5R,10R,13R,14S,17S)−17−(2−エチルスルファニルアセチル)−2,3,14−トリヒドロキシ−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン
94:(2S,3R,5R,10R,13R,14S,17S)−2,3,14−トリヒドロキシ−17−[2−(2−ヒドロキシエチルスルファニル)アセチル]−10,13−ジメチル−2,3,4,5,9,11,12,15,16,17−デカヒドロ−1H−シクロペンタ[a]フェナントレン−6−オン、から選択される化合物。 - 薬剤としての、請求項1〜10のいずれか一項に記載の化合物。
- 哺乳動物におけるサルコペニア、特にサルコペニア肥満と、関連合併症、及び/又はその病状、例えば筋力、筋肉量、身体能力・体力、運動性の低下などの治療及び/又は予防において使用するための、請求項1〜11のいずれか一項に記載の化合物。
- 哺乳動物における肥満と、その関連合併症、及び/又は関連病状、好ましくは2型糖尿病もしくはメタボリックシンドロームの治療及び/又は予防において使用するための、請求項1〜11のいずれか一項に記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1454538A FR3021318B1 (fr) | 2014-05-20 | 2014-05-20 | Produits derives de la 20-hydroxyecdysone et leur utilisation dans la preparation de medicaments |
FR1454538 | 2014-05-20 | ||
PCT/FR2015/051332 WO2015177469A1 (fr) | 2014-05-20 | 2015-05-20 | Composés chimiques et leur utilisation pour l'amélioration de la qualité musculaire |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017516851A true JP2017516851A (ja) | 2017-06-22 |
JP2017516851A5 JP2017516851A5 (ja) | 2018-06-28 |
JP6621217B2 JP6621217B2 (ja) | 2019-12-18 |
Family
ID=51518935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017513358A Active JP6621217B2 (ja) | 2014-05-20 | 2015-05-20 | 化合物及び筋肉の質を改善するためのその使用 |
Country Status (15)
Country | Link |
---|---|
US (2) | US9938315B2 (ja) |
EP (2) | EP3461833A1 (ja) |
JP (1) | JP6621217B2 (ja) |
KR (1) | KR102506149B1 (ja) |
CN (1) | CN106536539B (ja) |
AU (1) | AU2015263121B2 (ja) |
CA (1) | CA2949649A1 (ja) |
ES (1) | ES2732460T3 (ja) |
FR (1) | FR3021318B1 (ja) |
IL (1) | IL249062A0 (ja) |
PL (1) | PL3145942T3 (ja) |
PT (1) | PT3145942T (ja) |
RU (1) | RU2724329C2 (ja) |
TR (1) | TR201909078T4 (ja) |
WO (1) | WO2015177469A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021516228A (ja) * | 2018-02-28 | 2021-07-01 | ビオフィティス | 固定中の筋力低下の防止に使用する植物エクジソン |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3065644B1 (fr) * | 2017-04-28 | 2020-02-21 | Biophytis | Extrait de 20-hydroxyecdysone de qualite pharmaceutique, son utilisation et sa preparation |
FR3093641B1 (fr) * | 2019-03-15 | 2023-11-03 | Biophytis | Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de l’altération de la fonction respiratoire |
FR3093640B1 (fr) | 2019-03-15 | 2021-10-01 | Biophytis | Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de maladies neuromusculaires |
FR3108504B1 (fr) | 2020-03-30 | 2023-03-31 | Biophytis | Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement d’altérations de la fonction respiratoire lors d’une infection virale |
US20240083936A1 (en) * | 2020-12-17 | 2024-03-14 | University Of Florida Research Foundation, Incorporated | Steroidal compound derivatives as therapeutic agents |
FR3128873A1 (fr) | 2021-11-10 | 2023-05-12 | Biophytis | Phytoecdysones et/ou dérivés de 20-hydroxyecdysone en combinaison avec un principe actif visant à restaurer l’expression SMN pour leur utilisation dans le traitement de l’amyotrophie spinale |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006007910A1 (en) * | 2004-07-20 | 2006-01-26 | Santhera Pharmaceuticals (Schweiz) Ag | Use of non-glucocorticoid steroids for the treatment of muscular dystrophy |
WO2007100722A2 (en) * | 2006-02-28 | 2007-09-07 | Trustees Of Boston University | Methods to identify factors associated with muscle growth and uses thereof |
JP2011518121A (ja) * | 2008-03-14 | 2011-06-23 | イントレキソン コーポレーション | ステロイドリガンドおよび遺伝子スイッチモジュレーションにおけるその使用 |
WO2013088084A1 (fr) * | 2011-12-13 | 2013-06-20 | Institut Biophytis Sas | Phytoecdysones pour leur utilisation dans l'amélioration de la qualité musculaire de mammifères obèses et/ou sarcopéniques |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2982489B1 (fr) * | 2011-11-10 | 2013-12-27 | Inst Biophytis Sas | Phytoecdysones pour leur utilisation dans la stabilisation du poids apres un regime amaigrissant |
-
2014
- 2014-05-20 FR FR1454538A patent/FR3021318B1/fr active Active
-
2015
- 2015-05-20 PL PL15732785T patent/PL3145942T3/pl unknown
- 2015-05-20 KR KR1020167035614A patent/KR102506149B1/ko active IP Right Grant
- 2015-05-20 ES ES15732785T patent/ES2732460T3/es active Active
- 2015-05-20 US US15/311,967 patent/US9938315B2/en active Active
- 2015-05-20 WO PCT/FR2015/051332 patent/WO2015177469A1/fr active Application Filing
- 2015-05-20 TR TR2019/09078T patent/TR201909078T4/tr unknown
- 2015-05-20 CA CA2949649A patent/CA2949649A1/fr not_active Abandoned
- 2015-05-20 AU AU2015263121A patent/AU2015263121B2/en active Active
- 2015-05-20 EP EP18205305.8A patent/EP3461833A1/fr not_active Withdrawn
- 2015-05-20 CN CN201580038427.3A patent/CN106536539B/zh active Active
- 2015-05-20 PT PT15732785T patent/PT3145942T/pt unknown
- 2015-05-20 RU RU2016149619A patent/RU2724329C2/ru active
- 2015-05-20 EP EP15732785.9A patent/EP3145942B1/fr active Active
- 2015-05-20 JP JP2017513358A patent/JP6621217B2/ja active Active
-
2016
- 2016-11-20 IL IL249062A patent/IL249062A0/en unknown
-
2018
- 2018-04-09 US US15/949,010 patent/US10316056B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006007910A1 (en) * | 2004-07-20 | 2006-01-26 | Santhera Pharmaceuticals (Schweiz) Ag | Use of non-glucocorticoid steroids for the treatment of muscular dystrophy |
WO2007100722A2 (en) * | 2006-02-28 | 2007-09-07 | Trustees Of Boston University | Methods to identify factors associated with muscle growth and uses thereof |
JP2011518121A (ja) * | 2008-03-14 | 2011-06-23 | イントレキソン コーポレーション | ステロイドリガンドおよび遺伝子スイッチモジュレーションにおけるその使用 |
WO2013088084A1 (fr) * | 2011-12-13 | 2013-06-20 | Institut Biophytis Sas | Phytoecdysones pour leur utilisation dans l'amélioration de la qualité musculaire de mammifères obèses et/ou sarcopéniques |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021516228A (ja) * | 2018-02-28 | 2021-07-01 | ビオフィティス | 固定中の筋力低下の防止に使用する植物エクジソン |
JP7386798B2 (ja) | 2018-02-28 | 2023-11-27 | ビオフィティス | 固定中の筋力低下の防止に使用する植物エクジソン |
Also Published As
Publication number | Publication date |
---|---|
RU2016149619A (ru) | 2018-06-20 |
RU2016149619A3 (ja) | 2018-11-19 |
IL249062A0 (en) | 2017-01-31 |
US20180327444A1 (en) | 2018-11-15 |
KR20170027319A (ko) | 2017-03-09 |
AU2015263121A1 (en) | 2017-01-12 |
CN106536539A (zh) | 2017-03-22 |
CA2949649A1 (fr) | 2015-11-26 |
JP6621217B2 (ja) | 2019-12-18 |
US9938315B2 (en) | 2018-04-10 |
WO2015177469A1 (fr) | 2015-11-26 |
TR201909078T4 (tr) | 2019-07-22 |
FR3021318A1 (fr) | 2015-11-27 |
PT3145942T (pt) | 2019-07-04 |
RU2724329C2 (ru) | 2020-06-23 |
AU2015263121B2 (en) | 2018-12-06 |
US10316056B2 (en) | 2019-06-11 |
US20170226151A1 (en) | 2017-08-10 |
CN106536539B (zh) | 2020-01-07 |
EP3145942A1 (fr) | 2017-03-29 |
ES2732460T3 (es) | 2019-11-22 |
KR102506149B1 (ko) | 2023-03-07 |
FR3021318B1 (fr) | 2017-04-28 |
EP3145942B1 (fr) | 2019-04-03 |
PL3145942T3 (pl) | 2019-10-31 |
BR112016027053A8 (pt) | 2022-11-29 |
EP3461833A1 (fr) | 2019-04-03 |
BR112016027053A2 (pt) | 2017-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6621217B2 (ja) | 化合物及び筋肉の質を改善するためのその使用 | |
US10882835B2 (en) | KDM1A inhibitors for the treatment of disease | |
JP2019023200A (ja) | バルドキソロンメチルの2,2−ジフルオロプロピオンアミド誘導体、それらの多形体および使用方法 | |
JP6356888B2 (ja) | 疾患を治療するための、NF−κBの非ホルモン性ステロイド調節因子 | |
JP2002505668A (ja) | 環状エーテルビタミンD3化合物、1α(OH)3−エピ−ビタミンD3化合物及びそれらの使用法 | |
EP3148970B1 (en) | Androgen receptor modulators and methods for their use | |
EP3341380A1 (en) | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia | |
US11345705B2 (en) | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | |
US10464967B2 (en) | Non-hormonal steroid modulators of NF-κβ for treatment of disease | |
KR20230159466A (ko) | 구아이안계 세스퀴테르펜 유도체 및 이의 제약 용도 | |
WO2020018997A1 (en) | 3,4-thiazolo steroids and methods of making and using the same | |
BR112016027053B1 (pt) | Composto e usos de um composto | |
WO2016044559A1 (en) | C-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions | |
EP3724195A1 (en) | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
KR20170097673A (ko) | Cns 장애의 치료에서 사용하기 위한 3.알파.-에타인일, 3.베타.-하이드록시-5.알파.-프레그난-20-옥심 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170209 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20170209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180515 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180515 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190625 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190925 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191023 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6621217 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |